PROGNOSTIC VALUE OF ANEMIA IN NEWLY DIAGNOSED METASTATIC PROSTATE CANCER: A MULTIVARIATE ANALYSIS OF SOUTHWEST ONCOLOGY GROUP STUDY 8894

Newly Diagnosed ◽

Oncology Group ◽

Oncology Group Study ◽

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

Cancer ◽

10.1002/1097-0142(19930615)71:12<3975::aid-cncr2820711229>3.0.co;2-d ◽

1993 ◽

Vol 71 (12) ◽

pp. 3975-3978 ◽

Cited By ~ 15

Author(s):

Antoinette J. Wozniak ◽

Brent A. Blumenstein ◽

E. David Crawford ◽

Michael Boileau ◽

Saul E. Rivkin ◽

...

Keyword(s):

Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study

European Journal of Cancer ◽

10.1016/s0959-8049(05)80080-2 ◽

1992 ◽

Vol 28 (2-3) ◽

pp. 477-478 ◽

Cited By ~ 17

Author(s):

C.K. Osborne ◽

G.R. Weiss ◽

B.A. Blumenstein ◽

E.D. Crawford ◽

R.M. Bukowski ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Oncology Group ◽

Oncology Group Study ◽

1197: Prognostic Value of Hemoglobin Change after Initiation of Androgen Deprivations Therapy for Newly Diagnosed Metastatic Prostate Cancer: A Multivariate Analysis of Swog 8894

The Journal of Urology ◽

10.1016/s0022-5347(18)33422-0 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 385-386

Author(s):

Tomasz M. Beer ◽

Bryan H. Goldman ◽

Catherine M. Tangen ◽

Lisa B. Bland ◽

Maha Hussain ◽

...

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Prognostic Value ◽

Newly Diagnosed

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)

10.1200/jco.2004.22.90140.4510 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4510-4510 ◽

Cited By ~ 4

Author(s):

M. Hussain ◽

J. Faulkner ◽

U. Vaishampayan ◽

P. Lara ◽

D. Petrylak ◽

...

Keyword(s):

Prostate Cancer ◽

Hormone Refractory Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Epothilone B ◽

Hormone Refractory

Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109

Urology ◽

10.1016/j.urology.2011.11.019 ◽

2012 ◽

Vol 79 (3) ◽

pp. 633-637 ◽

Cited By ~ 24

Author(s):

Ryan K. Berglund ◽

Catherine M. Tangen ◽

Isaac J. Powell ◽

Bruce A. Lowe ◽

Gabriel P. Haas ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Neoadjuvant Therapy ◽

Oncology Group ◽

Oncology Group Study ◽

Goserelin Acetate

Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study

Annals of Oncology ◽

10.1093/annonc/mdp460 ◽

2010 ◽

Vol 21 (6) ◽

pp. 1196-1202 ◽

Cited By ~ 26

Author(s):

J.W. Sweetenham ◽

B. Goldman ◽

M.L. LeBlanc ◽

J.R. Cook ◽

R.R. Tubbs ◽

...

Keyword(s):

Monoclonal Antibody ◽

T Cells ◽

Prognostic Value ◽

Antibody Therapy ◽

Monoclonal Antibody Therapy ◽

Oncology Group ◽

Oncology Group Study ◽

Before And After ◽

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916

10.1200/jco.2004.22.14_suppl.4505 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4505-4505 ◽

Cited By ~ 3

Author(s):

E. D. Crawford ◽

D. K. Pauler ◽

C. M. Tangen ◽

M. H. A. Hussain ◽

E. J. Small ◽

...

Keyword(s):

Prostate Cancer ◽

Surrogate Endpoint ◽

Hormone Refractory Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Hormone Refractory

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916

10.1200/jco.2004.22.90140.4505 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4505-4505

Author(s):

E. D. Crawford ◽

D. K. Pauler ◽

C. M. Tangen ◽

M. H. A. Hussain ◽

E. J. Small ◽

...

Keyword(s):

Prostate Cancer ◽

Surrogate Endpoint ◽

Hormone Refractory Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Hormone Refractory

A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results

10.1200/jco.2008.26.15_suppl.8521 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8521-8521 ◽

Cited By ~ 14

Author(s):

J. A. Zonder ◽

J. J. Crowley ◽

V. Bolejack ◽

M. A. Hussein ◽

D. F. Moore ◽

...

Keyword(s):

Multiple Myeloma ◽

Newly Diagnosed ◽

Oncology Group ◽

Oncology Group Study ◽

Cytogenetic Abnormalities ◽

Study Results ◽

Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024

The Journal of Urology ◽

10.1016/j.juro.2006.03.068 ◽

2006 ◽

Vol 176 (2) ◽

pp. 548-553 ◽

Cited By ~ 7

Author(s):

Gregory P. Swanson ◽

James Faulkner ◽

Stephen R. Smalley ◽

Mark J. Noble ◽

Ronald L. Stephens ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Locally Advanced ◽

Oncology Group ◽

Locally Advanced Prostate Cancer ◽

Oncology Group Study ◽